Loading…
Agenus Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -88.7% over 5Y.
today you would have $82.88▼ -91.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.14 | $2.74 | $16.60 | $47.11 | $63.20 | $62.41 | $79.88 | $46.71 | $63.98 | $80.86 | $89.11 | $77.92 | $51.82 | $80.47 | $39.25 | $118.94 | $75.37 | |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 22.4 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MOBIMobia Medical, Inc. | $11.34 | — | 2.2x | — | — | $377.52M |
| TKNOAlpha Teknova, Inc. | $7.12 | — | 5.5x | — | -24.19% | $382.26M |
| AUNAAUNA S.a | $5.18 | 86.3x | 0.7x | — | 1.62% | $383.61M |
| BBOTBridgeBio Oncology Therapeutics, Inc. | $4.66 |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Company description provided by Yahoo Finance.
| P/S |
| 7.8x |
| 1.1x |
| 0.7x |
| 2.2x |
| 8.1x |
| 2.8x |
| 7.4x |
| 4.4x |
| 8.7x |
| 7.8x |
| 17.9x |
| 15.8x |
| 40.3x |
| 53.9x |
| 6.5x |
| 16.3x |
| — |
| — |
| P/B | 12.2x | — | — | — | — | 24.0x | — | — | — | — | — | 5.6x | 12.2x | — | — | — | — | — |
| EPS | $0.00 | -$10.59 | -$13.75 | -$15.64 | -$2.20 | -$20.61 | -$15.70 | -$28.26 | -$24.14 | -$28.66 | -$22.18 | -$13.94 | -$21.98 | -$10.01 | -$23.75 | -$27.67 | -$46.32 |
| Profit margin | -281.48% | -2.70% | -224.50% | -164.69% | -235.31% | -9.71% | -207.43% | -74.35% | -440.53% | -281.48% | -562.59% | -354.12% | -608.91% | -987.54% | -70.95% | -844.63% | -652.05% | -909.22% |
| ROE | -124.25% | — | — | — | — | -83.40% | — | — | — | — | — | -124.25% | -184.57% | — | — | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+733.0% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 1.2x |
| — |
| -81.92% |
| $373.61M |
| SLPSimulations Plus, Inc. | $18.41 | 46.0x | 2.7x | — | 6.17% | $372.34M |
| OFIXOrthofix Medical Inc. | $9.70 | — | 0.9x | — | -13.91% | $392.09M |